Mateon Therapeutics Inc (MATN) financial statements (2021 and earlier)

Company profile

Business Address 29397 AGOURA RD.
AGUORA HILLS, CA 91301
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 011122730
Cash and cash equivalents 01142730
Short-term investments    9  
Other undisclosed cash, cash equivalents, and short-term investments    (0)  
Receivables 0     
Prepaid expense    2 0
Other current assets      0
Other undisclosed current assets 00000 
Total current assets: 011142730
Noncurrent Assets
Property, plant and equipment 0 0000
Intangible assets, net (including goodwill) 22     
Goodwill 21     
Intangible assets, net (excluding goodwill) 1     
Other noncurrent assets   0000
Other undisclosed noncurrent assets 1     
Total noncurrent assets: 23 0000
TOTAL ASSETS: 2411142730
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 211212
Accounts payable 211000
Accrued liabilities 000000
Employee-related liabilities  00111
Debt 1     
Derivative instruments and hedges, liabilities 1     
Due to related parties 1     
Other undisclosed current liabilities 20101(0)
Total current liabilities: 712221
Noncurrent Liabilities
Total liabilities: 712221
Stockholders' equity
Stockholders' equity attributable to parent 17(0)(0)132529
Preferred stock 0     
Common stock 100000
Additional paid in capital 28294292291290280
Accumulated deficit (12)(295)(292)(278)(265)(251)
Total stockholders' equity: 17(0)(0)132529
TOTAL LIABILITIES AND EQUITY: 2411142730

Income statement (P&L) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:      (3)
Operating expenses (4)(3)(14)(14)(14)(13)
Other undisclosed operating income      3
Operating loss: (4)(3)(14)(14)(14)(13)
Nonoperating income (expense) (2)00000
Investment income, nonoperating 000000
Other nonoperating income (expense)  (0)(0)(0)0(0)
Interest and debt expense (1)     
Loss before gain (loss) on sale of properties: (7)(3)(14)(14)(14)(13)
Other undisclosed net income  0    
Net loss: (7)(3)(14)(14)(14)(13)
Other undisclosed net income attributable to parent 1     
Net loss available to common stockholders, diluted: (7)(3)(14)(14)(14)(13)

Comprehensive Income ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss: (7)(3)(14)(14)(14)(13)
Comprehensive loss, net of tax, attributable to parent: (7)(3)(14)(14)(14)(13)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: